<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Virtual screening Archives - Pharmacelera | Pushing the limits of computational chemistry</title>
	<atom:link href="https://pharmacelera.com/blog/tag/virtual-screening/feed/" rel="self" type="application/rss+xml" />
	<link></link>
	<description></description>
	<lastBuildDate>Mon, 27 Apr 2026 14:02:45 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://pharmacelera.com/wp-content/uploads/2022/04/cropped-Linkedin-avatar-32x32.png</url>
	<title>Virtual screening Archives - Pharmacelera | Pushing the limits of computational chemistry</title>
	<link></link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>VAST Novel Chemical Space Integrated with exaScreen® to Leverage 3D Ultra-Large Chemical Spaces</title>
		<link>https://pharmacelera.com/blog/partnerships/vast-novel-chemical-space-integrated-with-exascreen/</link>
		
		<dc:creator><![CDATA[Enric Herrero]]></dc:creator>
		<pubDate>Mon, 27 Apr 2026 12:59:23 +0000</pubDate>
				<category><![CDATA[Partnerships]]></category>
		<category><![CDATA[exascreen]]></category>
		<category><![CDATA[partnership]]></category>
		<category><![CDATA[VAST]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<category><![CDATA[XtalPi]]></category>
		<guid isPermaLink="false">https://pharmacelera.com/?p=15155</guid>

					<description><![CDATA[<p>Barcelona, Spain, and Cambridge, United States – April 28th – Pharmacelera, the leading provider of advanced computational tools for drug discovery, and [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/partnerships/vast-novel-chemical-space-integrated-with-exascreen/">VAST Novel Chemical Space Integrated with exaScreen® to Leverage 3D Ultra-Large Chemical Spaces</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="15155" class="elementor elementor-15155" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-56661cf elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="56661cf" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-a0b1f29" data-id="a0b1f29" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-95e7f41 elementor-widget elementor-widget-text-editor" data-id="95e7f41" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Barcelona, Spain, and Cambridge, United States – April 28<sup>th</sup> </strong>– <strong>Pharmacelera</strong>, the leading provider of advanced computational tools for drug discovery, and <strong>XtalPi</strong>, a pioneering Drug Discovery powered by AI and Automation, today announced the launch of a powerful new joint solution that integrates the <strong>XtalPi’s VAST</strong><strong><sup>TM </sup>library</strong> with Pharmacelera’s flagship virtual screening platform, <strong><a href="https://pharmacelera.com/exascreen/">exaScreen</a><sup>®</sup></strong>. This launch will provide researchers with unprecedented access to synthetically tractable chemical space combined with cutting-edge 3D computational methods for hit and lead discovery.</p>
<p>As the pharmaceutical industry increasingly turns to ultra-large libraries to identify novel hits, the challenge lies in <strong>navigating chemical diversity accurately while ensuring synthetic feasibility</strong>. The new joint solution directly addresses this challenge by combining <strong>Pharmacelera’s advanced Quantum-Mechanics-based tools</strong> with the <strong>XtalPi VAST</strong><strong><sup>TM</sup> chemical space</strong>, a curated collection of chemically diverse and highly synthesizable compounds.</p>
<p>With this launch, researchers can:</p>
<ul>
<li>Conduct accurate and efficient virtual screening across the <a href="https://www.aifchem.com/vast" target="_blank" rel="noopener">VAST</a><sup>TM</sup> library either through the licensing of the technology or through service projects</li>
<li>Rapidly source and synthesize compounds for experimental validation.</li>
<li>Expand opportunities to generate <strong>novel Intellectual Property (IP)</strong> through VAST<sup>TM</sup> chemical space and custom follow-up synthesis</li>
<li>Streamline the path from virtual prediction to real-world testing.</li>
</ul>								</div>
				</div>
				<div class="elementor-element elementor-element-0da9fa0 elementor-blockquote--skin-border elementor-widget elementor-widget-blockquote" data-id="0da9fa0" data-element_type="widget" data-e-type="widget" data-widget_type="blockquote.default">
				<div class="elementor-widget-container">
							<blockquote class="elementor-blockquote">
			<p class="elementor-blockquote__content">
				“The integration of the VAST chemical space into exaScreen® represents a major step forward for researchers. Together with Pharmacelera, we are enabling scientists to move seamlessly from computational insights to physical compounds with unmatched efficiency.”			</p>
							<div class="e-q-footer">
											<cite class="elementor-blockquote__author">Peiyu Zhang, Chief Science Officer of XtalPi</cite>
														</div>
					</blockquote>
						</div>
				</div>
				<div class="elementor-element elementor-element-7a0342a elementor-blockquote--skin-border elementor-widget elementor-widget-blockquote" data-id="7a0342a" data-element_type="widget" data-e-type="widget" data-widget_type="blockquote.default">
				<div class="elementor-widget-container">
							<blockquote class="elementor-blockquote">
			<p class="elementor-blockquote__content">
				“This launch is fully aligned with Pharmacelera’s mission to push the boundaries of computational drug discovery.”			</p>
							<div class="e-q-footer">
											<cite class="elementor-blockquote__author">Rémy Hoffmann, Chief Business Development Officer at Pharmacelera</cite>
														</div>
					</blockquote>
						</div>
				</div>
				<div class="elementor-element elementor-element-882b28a elementor-blockquote--skin-border elementor-widget elementor-widget-blockquote" data-id="882b28a" data-element_type="widget" data-e-type="widget" data-widget_type="blockquote.default">
				<div class="elementor-widget-container">
							<blockquote class="elementor-blockquote">
			<p class="elementor-blockquote__content">
				“We are thrilled to collaborate with XtalPi to apply our accurate QM- and ML-based algorithms to the VAST chemical Space, giving researchers access to a truly tractable and innovative chemical space.”			</p>
							<div class="e-q-footer">
											<cite class="elementor-blockquote__author"> Enric Gibert, CEO of Pharmacelera</cite>
														</div>
					</blockquote>
						</div>
				</div>
				<div class="elementor-element elementor-element-e4aa4ff elementor-widget-divider--view-line elementor-widget elementor-widget-divider" data-id="e4aa4ff" data-element_type="widget" data-e-type="widget" data-widget_type="divider.default">
				<div class="elementor-widget-container">
							<div class="elementor-divider">
			<span class="elementor-divider-separator">
						</span>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-2ebab0b elementor-widget elementor-widget-text-editor" data-id="2ebab0b" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong><em>About XtalPi</em></strong></p>
<p>XtalPi is an innovative technology platform company powered by artificial intelligence (Al) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the Life Sciences and new materials industries. With tightly interwoven quantum physics, Al, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.</p>
<p><strong>About Pharmacelera</strong></p>
<p>Pharmacelera is a deep-tech science-first company founded by experienced drug hunters, high-performance computing engineers, and leading academic researchers. The company has developed a proprietary in-silico platform that integrates accurate 3D Quantum-Mechanics (QM) models with advanced Artificial Intelligence (AI) algorithms to design novel, diverse, and high-quality molecules from ultra-large and previously untapped chemical spaces. Pharmacelera solutions provide access to its cutting-edge technology for HitID, H2L and LO. Founded in 2015 and with offices in Barcelona and Boston, Pharmacelera collaborates with leading pharmaceutical and biotech organizations across Europe and the United States.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://pharmacelera.com/blog/partnerships/vast-novel-chemical-space-integrated-with-exascreen/">VAST Novel Chemical Space Integrated with exaScreen® to Leverage 3D Ultra-Large Chemical Spaces</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Hit identification for  CCR2 using ultra-large virtual screening and FEP</title>
		<link>https://pharmacelera.com/blog/partnerships/case-study-in-ccr2-using-ultra-large-virtual-screening-and-fep/</link>
		
		<dc:creator><![CDATA[Fernando Martín]]></dc:creator>
		<pubDate>Wed, 26 Jun 2024 13:18:21 +0000</pubDate>
				<category><![CDATA[Partnerships]]></category>
		<category><![CDATA[exascreen]]></category>
		<category><![CDATA[Free Energy Perturbation]]></category>
		<category><![CDATA[PharmScreen]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://pharmacelera.com/?p=14622</guid>

					<description><![CDATA[<p>Barcelona, Leiden and Uppsala, July 2nd 2024 – Pharmacelera, the leading provider of computational tools for hit discovery, the Leiden Academic Center [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/partnerships/case-study-in-ccr2-using-ultra-large-virtual-screening-and-fep/">Hit identification for  CCR2 using ultra-large virtual screening and FEP</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="14622" class="elementor elementor-14622" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-08dee42 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="08dee42" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c3180ae" data-id="c3180ae" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b7784be elementor-widget elementor-widget-text-editor" data-id="b7784be" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Barcelona, Leiden and Uppsala, July 2nd 2024</strong> – Pharmacelera, the leading provider of computational tools for hit discovery, the Leiden Academic Center for Drug Research (LACDR) at Leiden University and MODSIM Pharma AB, the leading provider of physics-based biomolecular simulations tools, have announce the collaboration on a common project for the identification of new bio-active chemical entities for the C-C chemokine type 2 receptor (CCR2).</p><p>The project implies the combination of Computer-Aided Drug Design software with experimental validation and is performed in a sequential manner. The first stage consists in the identification of novel and diverse hits using exaScreen®, Pharmacelera proprietary technology, to perform a virtual screening of the Enamine REAL Space (48 billion compounds) based on 3D interaction fields derived from Quantum-Mechanics (QM) calculations. Selected candidates will be experimentally validated at the LACDR in a radioligand binding assay. Using this information, MODSIM Pharma will apply its proprietary <em>Free Energy Perturbation (FEP) </em>technology to optimize, prioritize and propose novel compounds that will be experimentally validated.</p><p>The research is part of the master&#8217;s project of Donald van Pinxteren, who will carry out the execution and analysis of the results obtained in the screening and FEP methods.</p><p>Working synergistically on this project reinforces the collaboration between Pharmacelera and MODSIM, and clearly highlight that integrated resources, expertise, and capabilities are key for speeding up drug discovery projects.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-b5f50b6 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="b5f50b6" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f0afc90" data-id="f0afc90" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-3ccc3f5 elementor-widget elementor-widget-text-editor" data-id="3ccc3f5" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>About Pharmacelera</strong></p><p><a href="https://pharmacelera.com/"><strong>Pharmacelera</strong> </a>develops advanced computational tools for the discovery of novel hits using accurate Quantum-Mechanics (QM), Artificial Intelligence (AI), and High-Performance Computing (HPC). The company’s products <a href="https://pharmacelera.com/pharmscreen/"><strong>PharmScreen</strong></a><strong>®, <a href="https://pharmacelera.com/exascreen/">exaScreen</a></strong>® and <a href="https://pharmacelera.com/pharmqsar/"><strong>PharmQSAR</strong></a>® use 3D molecular descriptors derived from Quantum-Mechanics (QM) calculations to mine an unexplored chemical space and to identify hits uncovered by traditional algorithms. Pharmacelera is a private company founded in 2015 and based in Barcelona, Spain. The company works with several big pharma and biotech organizations across Europe and the United States.</p><p><strong>About MODSIM Pharma AB</strong></p><p><a href="https://modsim-pharma.com/"><strong>MODSIM Pharma</strong></a> develops computational software and pipelines to increase the performance of structure-based drug discovery. The company has developed highly computationally efficient Free Energy Perturbation simulations protocols adapted for high-performance computing (HPC). The QresFEP module allows for systematic in-silico mutagenesis applicable to assess site-directed mutagenesis experiments or protein stability studies. With QligFEP, MODSIM Pharma can perform ligand optimization, scaffold hopping, linker length adjustment or postscoring pose ranking, based on accurate and systematic FEP simulations of ligand series. Initially focused on G protein-coupled receptors (GPCRs), the company has recently evolved the GPCR-Modsim web server, a one-stop shop for the 3D modeling and molecular dynamics (MD) simulations of GPCRs, into a generic membrane protein modeling and simulation package optimized for HPC.</p><p>MODSIM Pharma is a private company founded in 2018 and based in Uppsala, Sweden. The company offers the optimized combination of either module to address problems related to target characterization of structure-based ligand optimization and has agreements or contracts with different biotech and pharma companies.</p><p><strong>About LACDR</strong></p><p>The <a href="https://www.universiteitleiden.nl/en/science/drug-research"><strong>Leiden Academic Centre for Drug Research</strong></a> (LACDR) is a centre of excellence for multidisciplinary research on drug discovery and development. Despite major advances in medicine- research, many common diseases such as cancers, neurological or cardiovascular diseases, or auto-immune diseases, still lack effective treatment, or are still often found incurable. That is why our work to develop new and more effective drugs is essential. At the LACDR we work at the leading edge of drug-design and fundamental research of new drugs, optimization of existing drugs, and personalised medicine.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-8873f09 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="8873f09" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-53fa7b1" data-id="53fa7b1" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-40575c3 elementor-widget elementor-widget-text-editor" data-id="40575c3" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Media Contacts</strong></p><p><strong><u>Pharmacelera</u></strong></p><p>Rémy Hoffmann, CBDO (<a href="mailto:remy.hoffmann@pharmacelera.com">remy.hoffmann@pharmacelera.com</a>)</p><p><strong><u>MODSIM Pharma</u></strong></p><p>Hugo Gutiérrez de Terán, CEO (<a href="mailto:hugo@modsim-pharma.com">hugo@modsim-pharma.com</a>) </p><p><strong><u>University of Leiden</u></strong></p><p>Willem Jespers, Assistant Professor (<a href="mailto:w.jespers@lacdr.leidenuniv.nl">w.jespers@lacdr.leidenuniv.nl</a>)</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://pharmacelera.com/blog/partnerships/case-study-in-ccr2-using-ultra-large-virtual-screening-and-fep/">Hit identification for  CCR2 using ultra-large virtual screening and FEP</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>How can we screen 31 billion compounds? Divide and conquer!</title>
		<link>https://pharmacelera.com/blog/science/brute-force-vs-smart-enumeration/</link>
		
		<dc:creator><![CDATA[Fernando Martín]]></dc:creator>
		<pubDate>Tue, 30 May 2023 13:28:37 +0000</pubDate>
				<category><![CDATA[Science]]></category>
		<category><![CDATA[brute force]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[full enumeration]]></category>
		<category><![CDATA[smart enumeration]]></category>
		<category><![CDATA[ultra-large chemical libraries]]></category>
		<category><![CDATA[ultra-large chemical space]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://pharmacelera.com/?p=14024</guid>

					<description><![CDATA[<p>Commercial chemical libraries have witnessed remarkable growth in recent years, resulting in an unprecedented increase in size and diversity. With advancements in [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/science/brute-force-vs-smart-enumeration/">How can we screen 31 billion compounds? Divide and conquer!</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="14024" class="elementor elementor-14024" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-3227c28 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="3227c28" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-13397c9" data-id="13397c9" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b4bab92 elementor-widget elementor-widget-author-box" data-id="b4bab92" data-element_type="widget" data-e-type="widget" data-widget_type="author-box.default">
				<div class="elementor-widget-container">
							<div class="elementor-author-box">
							<div  class="elementor-author-box__avatar">
					<img decoding="async" src="https://pharmacelera.com/wp-content/uploads/2019/12/EnricHerrero_crop_BW-296x300.jpg" alt="Picture of Enric Herrero" loading="lazy">
				</div>
			
			<div class="elementor-author-box__text">
									<div >
						<h4 class="elementor-author-box__name">
							Enric Herrero						</h4>
					</div>
				
									<div class="elementor-author-box__bio">
						<p>May 30th, 2023</p>
					</div>
				
							</div>
		</div>
						</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-e8dc620 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="e8dc620" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-90fe1b3" data-id="90fe1b3" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-7a00464 elementor-widget elementor-widget-text-editor" data-id="7a00464" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Commercial chemical libraries have witnessed remarkable growth in recent years, resulting in an unprecedented increase in size and diversity. With advancements in high-throughput synthesis and combinatorial chemistry techniques, compound providers like Enamine have expanded their collections of small organic molecules to meet the escalating demands of the pharmaceutical industry. This exponential growth has provided researchers worldwide with access to an extraordinary wealth of chemical diversity, facilitating the discovery and development of novel therapeutic agents.</p><p>However, the significant growth in size and diversity of commercial chemical libraries has rendered previous methods of virtual screening impractical, especially for accurate 3D methods. The sheer volume of compounds amassed within these libraries presents immense challenges in terms of storage and computational costs. Taking as a reference a compressed SD file containing multiple stereoisomers and conformers of a molecule of 48KB, the fully enumerated library of <span style="color: #3366ff;"><a style="color: #3366ff;" href="https://enamine.net/compound-collections/real-compounds/real-database" target="_blank" rel="noopener"><b>Enamine REAL</b></a></span> (31 billion compounds) would require a storage capacity of 1.36 PB of data! This is almost 1400 hard drives like the one that you have in your laptop! Following the same example, if we assume that processing this single molecule requires 3.6 ms in your laptop, this will mean 3.5 years of calculations to perform a screening!</p><p>Luckily, several methods have been proposed that rely on the way these huge libraries are created, which is combining a set of building blocks to generate new molecules. Figure 1 shows an example of the value of using building blocks to perform a screening, for simplicity we will assume that each building block is a synthon and that all of them can be combined. In this example we have a building block library of 3 building blocks that can generate a chemical space of 9 molecules (combining all against all). If we apply the traditional approach (Brute force) we would compare our reference structure against each of the molecules of the library, this is 9 comparisons. However, if we perform a smart enumeration taking advantage of how this library has been created, we can reduce the computing cost. In this case what we would do is to partition the reference structure in two fragments and instead of comparing against all the enumerated library we perform the comparison against the building block library, this is 3 comparisons. Since we have two reference fragments we need to perform this operation twice, resulting in 6 comparisons, 3 less than in the brute force approach. This difference in the number of comparisons does not seem large but if we translate this example to a building block library of 100K building blocks, in the brute force approach we would need 10 million comparisons vs 200 thousand for the smart enumeration approach.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-3de58a7 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="3de58a7" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4e1bd8a" data-id="4e1bd8a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-fb16f19 elementor-widget elementor-widget-image" data-id="fb16f19" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
												<figure class="wp-caption">
										<img fetchpriority="high" decoding="async" width="1024" height="507" src="https://pharmacelera.com/wp-content/uploads/2023/05/Picture1-1024x507.png" class="attachment-large size-large wp-image-14026" alt="brute force against smart enumeration" srcset="https://pharmacelera.com/wp-content/uploads/2023/05/Picture1-1024x507.png 1024w, https://pharmacelera.com/wp-content/uploads/2023/05/Picture1-300x149.png 300w, https://pharmacelera.com/wp-content/uploads/2023/05/Picture1-768x380.png 768w, https://pharmacelera.com/wp-content/uploads/2023/05/Picture1.png 1312w" sizes="(max-width: 1024px) 100vw, 1024px" />											<figcaption class="widget-image-caption wp-caption-text">Figure 1. Comparison of a brute force search vs using building blocks (Smart Enumeration). </figcaption>
										</figure>
									</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-fa67fe0 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="fa67fe0" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d51bcad" data-id="d51bcad" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-c1d1ac2 elementor-widget elementor-widget-text-editor" data-id="c1d1ac2" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>If we plot the computational cost projections of both methods for different library sizes (Figure 2) we can see how the scalability of the smart enumeration approach is much better than the brute force approach and, therefore, is much more suitable for the chemical libraries of the future.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-2783d47 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="2783d47" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-cd29f7f" data-id="cd29f7f" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-1189e62 elementor-widget elementor-widget-image" data-id="1189e62" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
												<figure class="wp-caption">
										<img decoding="async" width="666" height="436" src="https://pharmacelera.com/wp-content/uploads/2023/05/Picture2.png" class="attachment-large size-large wp-image-14027" alt="" srcset="https://pharmacelera.com/wp-content/uploads/2023/05/Picture2.png 666w, https://pharmacelera.com/wp-content/uploads/2023/05/Picture2-300x196.png 300w" sizes="(max-width: 666px) 100vw, 666px" />											<figcaption class="widget-image-caption wp-caption-text">Figure 2. Computing time requirements in a single machine for Brute force and Smart Enumeration</figcaption>
										</figure>
									</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-5343ee9 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="5343ee9" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7188a7a" data-id="7188a7a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-cc4dce4 elementor-widget elementor-widget-text-editor" data-id="cc4dce4" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Overall, we have seen that the rapid growth of commercial chemical libraries represents a challenge for virtual screening tools. The size and diversity of these libraries have made traditional screening methods impractical due to storage and computational costs. However, the use of smart enumeration based on building blocks offers a more efficient approach. By leveraging the way these libraries are created, researchers can significantly reduce the number of comparisons needed for screening. This smart enumeration approach shows better scalability and is considered more suitable for future chemical libraries, offering computational efficiency compared to brute force methods.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://pharmacelera.com/blog/science/brute-force-vs-smart-enumeration/">How can we screen 31 billion compounds? Divide and conquer!</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Chemical diversity: why is it important to study it?</title>
		<link>https://pharmacelera.com/blog/science/chemical-diversity-why-is-it-important/</link>
		
		<dc:creator><![CDATA[Fernando Martín]]></dc:creator>
		<pubDate>Thu, 21 Jul 2022 13:05:23 +0000</pubDate>
				<category><![CDATA[Science]]></category>
		<category><![CDATA[chemical diversity]]></category>
		<category><![CDATA[Chemical space]]></category>
		<category><![CDATA[hit identification]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://pharmacelera.com/?p=13095</guid>

					<description><![CDATA[<p>By Giorgia Zaetta There are more than six hundred and seventy-five duodecillion possible chemical structures, but only a part of them, approximately [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/science/chemical-diversity-why-is-it-important/">Chemical diversity: why is it important to study it?</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="13095" class="elementor elementor-13095" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-e12611d elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="e12611d" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-4583500" data-id="4583500" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-f3d5a4a elementor-widget elementor-widget-image" data-id="f3d5a4a" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://pharmacelera.com/wp-content/uploads/2020/11/Giorgia_Z-e1649068863609.jpg" title="" alt="Giorgia Zaetta" loading="lazy" />															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-16af754" data-id="16af754" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-dc7e2b9 elementor-widget elementor-widget-text-editor" data-id="dc7e2b9" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>By Giorgia Zaetta</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-d9d3dd3 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="d9d3dd3" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-86230c1" data-id="86230c1" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b2ac5bd elementor-widget elementor-widget-text-editor" data-id="b2ac5bd" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>There are more than six hundred and seventy-five duodecillion possible chemical structures, but only a part of them, <a href="https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1098-1128(199601)16:1%3C3::AID-MED1%3E3.0.CO;2-6">approximately 10<sup>60</sup></a>, are potential pharmacologically active compounds. These molecules constitute the chemical space. The accessible (and synthesizable) chemical space grows exponentially every day, subsequently increasing the chances of finding new potential hits and lead compounds.</p><p>Although structure-based methods (SBM) provide detailed information about the binding mode between a compound and its target (when the structure of the target is available), this is a highly demanding task from a computational cost perspective, moreover if we want to access to this large chemical space. Here, ligand-based methods (LBM) provide an excellent alternative as we can screen larger number of compounds than with SBM while keeping similar physicochemical properties of the query compound. A question may appear at this point: how chemically diverse are the new compounds with respect to my query?</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-5d51709 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="5d51709" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e57f143" data-id="e57f143" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-926fc25 elementor-widget elementor-widget-heading" data-id="926fc25" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default">Searching for more chemically diverse compounds</h2>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-0e7c2e1 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="0e7c2e1" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6719725" data-id="6719725" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-199de4e elementor-widget elementor-widget-text-editor" data-id="199de4e" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Chemical diversity can be described as the distribution of compounds in the chemical space based on their physicochemical profile.<sup> </sup>As mentioned above, in early stages of drug discovery, it’s considerably time-consuming and computationally expensive to screen the large chemical space. For this reason, in addition to an optimal method to screen compounds, libraries that contain molecules with a set of desired properties (often project-dependent), or structures can be curated for a desired purpose, commonly generating small-molecule libraries.</p><p>However, structurally similar compounds may exhibit similar ADME/Tox issues, synthetic problems, or being covered under the same IP of a patent. Therefore, ideally, it is relevant to select a proper method that will allow you to find new chemical solutions that will overcome the limitations of your current compounds. The more structurally dissimilar compounds are found, the higher the chance of finding new hits.</p><p>At present, different methods describe chemical similarity when virtual screening is performed: structural keys, fingerprints, or molecular descriptors. While 2D similarity methods provide quick searches, they don’t consider the different conformers a molecule can adopt. 3D similarity methods can capture this information, calculating different conformers per molecule and comparing them to, for example, the bioactive conformation of a co-crystalized ligand. But even 3D methods can have some limitations in the identification of novel and diverse compounds, as some physicochemical properties are highly dependent of the conformer adopted by the molecule.</p><p>Pharmacelera’s technology enables screening large chemical libraries thanks to the use of extremely efficient algorithms in combination with our precise <strong><a href="https://pharmacelera.com/our-science/">3D semiempirical quantum mechanics molecular field descriptors</a></strong>. These algorithms not only find original structures but also take into consideration the synthesizability they have.</p><p>Studying chemical diversity, and looking for hits with different and novel features, is very important. Combining these algorithms and descriptors prompts to an efficient, accurate, and fast exploration of a large chemical space while also identifying original and synthesizable compounds.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-7b93e9d elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="7b93e9d" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2f57e47" data-id="2f57e47" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-628f166 elementor-widget elementor-widget-text-editor" data-id="628f166" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p style="text-align: center;"><strong>Want to learn more about our descriptors? </strong></p><p style="text-align: center;"><strong><a href="https://pharmacelera.com/contact-us/">Contact us</a> or ask for a <a href="https://pharmacelera.com/pharmscreen/">trial</a> of Pharm<span style="color: #ff9900;">Screen</span>!</strong></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://pharmacelera.com/blog/science/chemical-diversity-why-is-it-important/">Chemical diversity: why is it important to study it?</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>PharmScreen for Knime</title>
		<link>https://pharmacelera.com/blog/partnerships/pharmscreen-for-knime/</link>
		
		<dc:creator><![CDATA[Fernando Martín]]></dc:creator>
		<pubDate>Thu, 23 Apr 2020 07:26:48 +0000</pubDate>
				<category><![CDATA[Partnerships]]></category>
		<category><![CDATA[knime]]></category>
		<category><![CDATA[ligand-based drug discovery]]></category>
		<category><![CDATA[nodes]]></category>
		<category><![CDATA[PharmScreen]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://new.pharmacelera.com/?p=6571</guid>

					<description><![CDATA[<p>We are happy to announce that PharmScreen, our virtual screening tool is available for Knime. Knime is a free open-source platform that [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/partnerships/pharmscreen-for-knime/">PharmScreen for Knime</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>We are happy to announce that PharmScreen, our virtual screening tool<strong> <a href="https://www.knime.com/blog/virtual-screening-with-knime">is available for Knime</a></strong>. Knime is a free open-source platform that uses a modular pipeline concept for data analytics, reporting and integration. Knime links different open-source and third-party nodes and workflows, allowing the connection of different tools and methods for the analysis of different data sources, and using an intuitive graphical user interface.</p>



<p>Based on this modular concept, we have developed PharmScreen for Knime. This version includes a list of nodes to run virtual screening campaigns using our ligand-based approach. The nodes take advantage of our <strong>&nbsp;<a href="https://pharmacelera.com/better-molecular-description/">unique hydrophobic descriptors</a></strong> to mine the unexploited chemical space when screening compound libraries.  Additionally, we have implemented a list of workflows that will help you executing PharmScreen for different purposes. </p>



<h2 class="wp-block-heading">List of available nodes</h2>



<ul class="wp-block-list"><li><strong>The Ligand Preparation node</strong> enables the preparation of molecular libraries to run virtual screening campaigns. For instance, this includes conformer generation, minimization and partial charge, as well as LogP calculation.</li><li><strong>The Virtual Screening node</strong> enables the search of new and promising compounds using a field-based molecular alignment and comparison.</li></ul>



<figure class="wp-block-image size-large"><img decoding="async" width="1023" height="286" src="https://pharmacelera.com/wp-content/uploads/2020/04/2-virtual-screening-pharmacelera.png" alt="Pharmacelera workflow generated in Knime to run a virtual screening campaign" class="wp-image-6573" srcset="https://pharmacelera.com/wp-content/uploads/2020/04/2-virtual-screening-pharmacelera.png 1023w, https://pharmacelera.com/wp-content/uploads/2020/04/2-virtual-screening-pharmacelera-300x84.png 300w, https://pharmacelera.com/wp-content/uploads/2020/04/2-virtual-screening-pharmacelera-768x215.png 768w" sizes="(max-width: 1023px) 100vw, 1023px" /></figure>



<h2 class="wp-block-heading">List of available workflows</h2>



<ul class="wp-block-list"><li><strong>Pharmacelera_Standard_VS</strong>: Use this workflow to run a 3D ligand-based virtual screening campaign with PharmScreen in Knime.</li><li><strong>Pharmacelera_VS_Multiserver</strong>: Execute this workflow if you want to run your virtual screening campaign on a variable number of machines.</li><li><strong>Pharmacelera_LigandPreparation_Multiserver</strong>: Use this workflow to prepare you virtual screening library using a variable number of machines.</li><li><strong>Pharmacelera_VS_ROCcurve</strong>: Run a 3D ligand-based virtual screening benchmark with PharmScreen and generate the corresponding ROC curves .</li><li><strong>Pharmacelera_VS_ChEMBL_Search</strong>: This workflow will search the ligands obtained from PharmScreen’s virtual screening in the ChEMBL database.</li></ul>



<h2 class="wp-block-heading">How to get PharmScreen for Knime?</h2>



<p>You can directly download and install the different nodes and workflows in the <a href="https://hub.knime.com/pharmacelera/extensions/org.knime.pharmacelera.feature/latest/org.knime.pharmacelera.pslp.PSLPNodeFactory"><strong>Knime Hub</strong></a>. To run the nodes, <strong><a href="https://pharmacelera.com/ask-for-a-demo/">contact us for the corresponding license</a>.</strong></p>



<p> Are you looking for additional workflows? Let us know and we will be happy to <a href="contact@pharmacelera.com">help you</a>! </p>
<p>The post <a href="https://pharmacelera.com/blog/partnerships/pharmscreen-for-knime/">PharmScreen for Knime</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Measuring Virtual Screening Accuracy</title>
		<link>https://pharmacelera.com/blog/science/measuring-virtual-screening-accuracy/</link>
		
		<dc:creator><![CDATA[Fernando Martín]]></dc:creator>
		<pubDate>Wed, 11 Dec 2019 07:55:13 +0000</pubDate>
				<category><![CDATA[Science]]></category>
		<category><![CDATA[BEDROCS]]></category>
		<category><![CDATA[comparison]]></category>
		<category><![CDATA[metrics]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[ROCE]]></category>
		<category><![CDATA[ROCS]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://new.pharmacelera.com/?p=5693</guid>

					<description><![CDATA[<p>By Javier Vazquez &#8211; Dec. 11, 2019 Virtual Screening (VS) is a core in-silico technology in medicinal and computational chemistry. Several tools [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/science/measuring-virtual-screening-accuracy/">Measuring Virtual Screening Accuracy</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="5693" class="elementor elementor-5693" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-fdd6797 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="fdd6797" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-6410f01" data-id="6410f01" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-a18d09f elementor-widget elementor-widget-image" data-id="a18d09f" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img loading="lazy" decoding="async" width="697" height="715" src="https://pharmacelera.com/wp-content/uploads/2021/06/JV.jpg" class="attachment-large size-large wp-image-8184" alt="" srcset="https://pharmacelera.com/wp-content/uploads/2021/06/JV.jpg 697w, https://pharmacelera.com/wp-content/uploads/2021/06/JV-292x300.jpg 292w, https://pharmacelera.com/wp-content/uploads/2021/06/JV-230x236.jpg 230w, https://pharmacelera.com/wp-content/uploads/2021/06/JV-350x359.jpg 350w, https://pharmacelera.com/wp-content/uploads/2021/06/JV-480x492.jpg 480w" sizes="(max-width: 697px) 100vw, 697px" />															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-34c3130" data-id="34c3130" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-d75cbb0 elementor-widget elementor-widget-text-editor" data-id="d75cbb0" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>By Javier Vazquez &#8211; Dec. 11, 2019</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-79c8e78a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="79c8e78a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-505fb828" data-id="505fb828" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-25949b21 elementor-widget elementor-widget-text-editor" data-id="25949b21" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									
<p><p align="justify">Virtual Screening (VS) is a core in-silico technology in medicinal and computational chemistry. Several tools have been developed to exploit protein structures or collections of compounds to provide a quick and economical method for the discovery of novel active compounds. Hence, the comparative evaluation of VS algorithms becomes a fundamental exercise to assess the applicability of drug discovery tools. Here, we explain some metrics used to evaluate the accuracy of VS tools in retrospective studies, using known data sets of active and inactive compounds. The most common ones are <b>the area under the receiver operating characteristic (ROC) curve (AUC), the BEDROC score, the enrichment factor (EF)</b>, and <b>ROC enrichment (ROCe)</b>.</p></p>



<h3 class="wp-block-heading">How do we measure accuracy?</h3>



<p><p align="justify"><b>ROC curves</b> are one of the most used representations to compare VS algorithms performance. This kind of plot represents the relation between the fraction of true positives (active compounds) out of the total positives or sensitivity, versus the fraction of false positives out of the total negatives (inactive compounds) or specificity, as shown in Figure 1A. The closer the line to the upper left corner, the better, as it means that active molecules rank in the first positions of the ranking provided by a VS campaign.
</p></p>



<p><p align="justify">The most intuitive and easy way to compare ROC curves is the <b>AUC metric</b>, representing the area value under the ROC curve. AUC values range from 0 to 1, where 1 indicates a perfect classification of the screened compounds (i.e. all active compounds ranked before the inactive compounds). On the other hand, values lower than or equal to 0.5 are considered a bad prediction and are associated with a random classification.</p></p>



<p><p align="justify">The argument against using AUC values resides in the difficulty to characterize the initial part of a ranked list, particularly when we compare algorithms with high AUC score. . For example, an identical AUC value for two different VS methods (A and B) does not necessarily mean that both methods perform equally. As illustrated in Figure 1B, although methods A and B have the same AUC values, method A finds more active compounds in the initial part of the ranking, whereas method B retrieves more active compounds in the last part of the ranking.
</p></p>



<div class="wp-block-image"><figure class="aligncenter"><img loading="lazy" decoding="async" width="584" height="306" src="https://new.pharmacelera.com/wp-content/uploads/2019/12/roc2.png" alt="roc curve example and roc curve comparison between two approaches to measure virtual screening performance" class="wp-image-5696" srcset="https://pharmacelera.com/wp-content/uploads/2019/12/roc2.png 584w, https://pharmacelera.com/wp-content/uploads/2019/12/roc2-300x157.png 300w" sizes="(max-width: 584px) 100vw, 584px" /></figure></div>



<p><p align="justify">
<i><b>Figure 1.</b> (A), Example of ROC curve. Hits: known active compound. Decoys: assumed non-active compounds. The shaded section (blue) is the area under the receiver operating characteristic (ROC) curve (AUC). (B), ROC curves for two different VS methods. Although VS method A (redline line) addresses the ‘‘early recognition’’ problem better than VS method B (blue line), their AUC are equal.</i>
</p></p>



<h3 class="wp-block-heading">The early recognition problem</h3>



<p><p align="justify">Early recognition of active molecules is of paramount importance in real-world screening applications, where researchers only test top-ranked molecules in biological assays due to their high costs. Hence, it is easy to argue that in the example above, method A performs better than method B. To evaluate this early enrichment behavior, several metrics have been proposed:
</p></p>



<ul class="wp-block-list"><li align="justify"><b>The Boltzmann-Enhanced Discrimination of ROC (BEDROC)</b> is a metric<sup>1</sup> that assigns more weight to early ranked molecules than late ranked molecules. The active compounds are weighted depending on their position in the ranking using an exponential function, ranging from 1.0 for the top ranked compound to close to zero for the lowest ranked compound. The exponential factor determines how much the BEDROC parameter focuses on the top of the list.The drawbacks of this metric are its dependency of the ratio of active/inactive compounds and the dependency of an extrinsic variable (adjustable exponential factor). That means that the value depends on the method and a particular experiment. Hence, sets with different active/inactive compound ratios cannot be compared directly using such a metric.
</li></ul>



<ul class="wp-block-list"><li align="justify"><b>Enrichment Factor (EF)</b> measures the fraction of active compounds found in a specific percentage, solving the problem of comparing the results for datasets with different active / inactive compound ratios. EF is a quite standard metric due to its intuitive interpretation related to the purpose of the VS itself (the ability to select a subset of molecules with a promising chance of finding a hit compound). However, although the EF metric is independent of adjustable parameters, it is still inﬂuenced by the number of active compounds in the dataset.  EF becomes smaller if fewer inactive molecules are initially present.</li><li><b>ROC enrichment (ROCe)</b> is the fraction of active compounds divided by the fraction of false positive compounds at a specific percentage of decoys retrieved. It represents the ability of the test to discriminate between two populations: active and inactive compounds. This approach solves the active/inactive compound ratio dependency present in the previous metrics. This metric only gives information about a defined percentage. Jain and Nicholls<sup>2</sup> suggest the 0.5, 1.0, 2, and 5 percentages to report the “early enrichment” values.</li></ul>



<h3 class="wp-block-heading">Exploring the chemical diversity</h3>



<p><p align="justify">As discussed, several metrics solve the early recognition problem. But, none of them distinguish different scenarios regarding chemical diversity. In general, a VS tool that ranks a given number of active compounds of different chemical families in the first positions performs better than a tool that ranks the same number of active compounds but all belonging to the same or fewer chemical families. <a href="https://new.pharmacelera.com/science/clustering-methods-big-library-screening/"><b>Clustering is a commonly used technique to classify compounds into different chemical families</b></a> based on scaffold similarity. To account for chemical diversity, the ROC curve metrics have been adjusted as follows<sup>3</sup></p></p>



<ul class="wp-block-list"><li align="justify"><b>Average-weighted ROC curve (awROC)</b>. The above scheme can be also embedded into the ROC enrichment. Thus, the value of the true positive hit is weighted depending on the cluster to which it belongs to and on the number of molecules in the cluster.</li><li align="justify"><b>Average-weighted Area  Under  the  Curve  (awAUC)</b>,  can  be  interpreted  as  the probability that  an  active  compound  with  a new  scaffold  is  ranked  before  an  inactive compound. Using an arithmetic weighting, each structure has a weight that is inversely proportional to the size of the cluster it belongs to. Therefore, the weight of all structures taken from one cluster is equal. Integrating this scheme into the basic AUC leads to an arithmetic weighted version (awAUC).</li></ul>


<p align="justify">The main drawback of the metrics that account for chemical diversity is that they are very sensitive to the methodology that is used to group molecules into chemical families.
</p>


<h3 class="wp-block-heading">Conclusions</h3>



<p><p align="justify">As discussed, the characterization of VS performance is of paramount importance to assess the applicability of these technologies in drug discovery. Despite the common aim of benchmarking studies, there is still no consensus on what is the best metric/s to analyze and compare results. Establishing standards in the field of cheminformatics, particularly in VS, is necessary to enhance the quality of publications and allow a reliable assessment of methods and progress.
</p></p>



<p><p align="justify"><strong>What is your opinion in this regard? What metric/s are you using to assess virtual screening tools? Choose your preferred metric and leave your comments in the survey!
</p></p>



<div style="height:100px" aria-hidden="true" class="wp-block-spacer"></div>



<div class="wp-block-button aligncenter"><a class="wp-block-button__link has-very-dark-gray-color has-very-light-gray-background-color has-text-color has-background no-border-radius" href="https://forms.gle/egYukSunuG72iFRK8">Go to survey</a></div>



<div style="height:100px" aria-hidden="true" class="wp-block-spacer"></div>



<p>REFERENCES</p>



<p>(1) &nbsp;Truchon, J.-F.; Bayly, C. I. Evaluating Virtual Screening Methods:  Good and Bad Metrics for the “Early Recognition” Problem. <em>J. Chem. Inf. Model.</em> <strong>2007</strong>, <em>47</em> (2), 488–508.</p>



<p>(2) &nbsp;Jain, AN; Nicholls, A. Recommendations for Evaluation of Computational Methods. <strong>2008</strong>, <em>22</em>, 133–139.</p>



<p>(3) Clark, R. D.; Webster-Clark, D. J. Managing Bias in ROC Curves. <em>J. Comput. Aided. Mol. Des.</em> <strong>2008</strong>, <em>22</em> (3–4), 141–146.</p>
								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://pharmacelera.com/blog/science/measuring-virtual-screening-accuracy/">Measuring Virtual Screening Accuracy</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Are you considering tautomerism, ionization and chirality when identifying new hits?</title>
		<link>https://pharmacelera.com/blog/publications/tautomerism-ionization-chirality/</link>
		
		<dc:creator><![CDATA[Enric Gibert]]></dc:creator>
		<pubDate>Wed, 17 Jan 2018 14:41:51 +0000</pubDate>
				<category><![CDATA[Publications]]></category>
		<category><![CDATA[chirality]]></category>
		<category><![CDATA[computational chemistry]]></category>
		<category><![CDATA[drug design]]></category>
		<category><![CDATA[enantiomer]]></category>
		<category><![CDATA[ionization]]></category>
		<category><![CDATA[protonation]]></category>
		<category><![CDATA[tautomer]]></category>
		<category><![CDATA[tautomerism]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://www.pharmacelera.com/?p=3322</guid>

					<description><![CDATA[<p>Tautomerism, ionization and chirality are important factors to consider when building a compound library or when finding new hits. Tautomerism and ionization The [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/publications/tautomerism-ionization-chirality/">Are you considering tautomerism, ionization and chirality when identifying new hits?</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;"><strong>Tautomerism, ionization and chirality </strong></span><span style="font-weight: 400;">are </span><strong>important factors</strong> to<span style="font-weight: 400;"> consider when building a</span><b> compound library </b><span style="font-weight: 400;">or </span><b>when finding new hits.</b></p>
<h3>Tautomerism and ionization</h3>
<p><span style="font-weight: 400;">The <strong>interactions</strong> between a ligand and a target protein can be <strong>significantly affected as a result of tautomerism and ionization</strong>, potentially having a direct impact when identifying new hits for a given receptor. Hence, the enumeration of the tautomeric and protonation (ionization) states are an <strong>important step in in-silico drug discovery</strong> tasks such as virtual screening.</span></p>
<p><b>Tautomers </b><span style="font-weight: 400;">are isomers<strong> differing only in the positions of hydrogen atoms and electrons.</strong> Even a simple molecule can have several different tautomeric forms. Moreover, acid/base equilibrium, which explores different protonation states by assigning formal charges to those chemical moieties that are likely to be charged (e.g., phosphate or guanidine) under different conditions,  produces additional forms called </span><b>protomers</b><span style="font-weight: 400;">.</span></p>
<p><img loading="lazy" decoding="async" class="size-medium wp-image-3329 aligncenter" src="https://pharmacelera.com/wp-content/uploads/2018/01/tautormeros-300x179.jpg" alt="" width="300" height="179" srcset="https://pharmacelera.com/wp-content/uploads/2018/01/tautormeros-300x179.jpg 300w, https://pharmacelera.com/wp-content/uploads/2018/01/tautormeros.jpg 577w" sizes="(max-width: 300px) 100vw, 300px" /></p>
<p><span style="font-weight: 400;">Many factors can inﬂuence the tautomeric and protonation equilibriums, such as </span><b>concentration, temperature, and pH</b><span style="font-weight: 400;">. Tautomers and protomers differ in shape, functional groups, surface, and hydrogen bonding. Therefore,</span><b> tautomerism and protonation may result in alternative binding modes</b><span style="font-weight: 400;"> with the corresponding impact on ligand/protein interactions.</span></p>
<p><span style="font-weight: 400;">For instance, Polgar and co-workers have studied the impact of ligand protonation on virtual screening against BACE1 [1]. As an a<strong>dditional proof of the importance</strong> of these factors, the widely used ZINC database is<strong> processed to generate relevant tautomers and protomers</strong> between pH 5 and 9.5.</span></p>
<p>However, a lot of works <b>do not consider these aspects </b>when building databases or when performing virtual screening due to the <b>perceived underlying complexity.</b></p>
<h3>Chirality</h3>
<p>In addition, <b>chirality </b>is also a <strong>crucial factor in drug discovery</strong>. The presence of an asymmetric carbon atom  (chiral carbon) causes two stereoisomers (non-superposable mirror images of each other), which can show a remarkable difference in the effect of their biological action.</p>
<p>For example, <b>ephedrine </b>has been used for asthma, whereas its enantiomer,  <b>pseudoephedrine, </b>is a nasal/sinus decongestant.</p>
<p><img loading="lazy" decoding="async" class="wp-image-3336 aligncenter" src="https://pharmacelera.com/wp-content/uploads/2018/01/epiandpseudo.jpg" alt="" width="528" height="180" srcset="https://pharmacelera.com/wp-content/uploads/2018/01/epiandpseudo.jpg 900w, https://pharmacelera.com/wp-content/uploads/2018/01/epiandpseudo-300x102.jpg 300w, https://pharmacelera.com/wp-content/uploads/2018/01/epiandpseudo-768x261.jpg 768w" sizes="(max-width: 528px) 100vw, 528px" /></p>
<p style="text-align: center;"><i><span style="font-weight: 400;">Ephedrine on the left side which is the (S) isomer and pseudoephedrine on the right side which is the (R) isomer</span></i></p>
<p><span style="font-weight: 400;">As other examples related to chirality, only <strong>the (S) isomer of </strong></span><strong>ibuprofen</strong><span style="font-weight: 400;"> is <strong>effective</strong>, whereas the <strong>(R) isomer has no anti-inflammatory action</strong> and the antihypertensive drug </span>methyldopa owes<span style="font-weight: 400;"> its effect exclusively to the (S) isomer.  </span></p>
<p><img loading="lazy" decoding="async" class="alignright size-full wp-image-3339" src="https://pharmacelera.com/wp-content/uploads/2018/01/ibupomethyl.jpg" alt="" width="900" height="306" srcset="https://pharmacelera.com/wp-content/uploads/2018/01/ibupomethyl.jpg 900w, https://pharmacelera.com/wp-content/uploads/2018/01/ibupomethyl-300x102.jpg 300w, https://pharmacelera.com/wp-content/uploads/2018/01/ibupomethyl-768x261.jpg 768w" sizes="(max-width: 900px) 100vw, 900px" /></p>
<p style="text-align: center;"><em><span style="font-weight: 400;">Ibuprofen on the left side </span><span style="font-weight: 400;">and methyldopa on </span><span style="font-weight: 400;">the right side which both are (S) isomers.</span></em></p>
<p><span style="font-weight: 400;">In conclusion, t<strong>automerism, ionization and <b>chirality </b></strong>are factors that<strong> affect the interactions between a ligand and a target protein</strong> and they<strong> should be handled properly in in-silico drug design projects.</strong></span></p>
<p><small> [1]  <span style="font-weight: 400;">Tímea Polgár, Csaba Magyar, István Simon, and György M. Keserü. “Impact of Ligand Protonation on Virtual Screening against β-Secretase (BACE1)”. Journal of Chemical Information and Modeling </span><b>2007</b> <i><span style="font-weight: 400;">47</span></i><span style="font-weight: 400;"> (6), 2366-2373. </span><span style="font-weight: 400;">DOI: 10.1021/ci700223p</span></small></p>
<p>&nbsp;</p>
<p>The post <a href="https://pharmacelera.com/blog/publications/tautomerism-ionization-chirality/">Are you considering tautomerism, ionization and chirality when identifying new hits?</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Alignment of PIM-1 Inhibitors with PharmScreen</title>
		<link>https://pharmacelera.com/blog/science/alignment-of-pim-1-inhibitors-with-pharmascreen/</link>
		
		<dc:creator><![CDATA[Enric Gibert]]></dc:creator>
		<pubDate>Wed, 06 Dec 2017 11:13:02 +0000</pubDate>
				<category><![CDATA[Science]]></category>
		<category><![CDATA[computational chemistry]]></category>
		<category><![CDATA[computer aided drug design]]></category>
		<category><![CDATA[drug design]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[PharmScreen]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://www.pharmacelera.com/?p=3239</guid>

					<description><![CDATA[<p>Pim-1 is an oncogene-encoded serine/threonine kinase. Originally identified in Maloney murine leukaemia, it is involved in several cellular functions associated with survival [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/science/alignment-of-pim-1-inhibitors-with-pharmascreen/">Alignment of PIM-1 Inhibitors with PharmScreen</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="http://www.uniprot.org/uniprot/P11309"><b>Pim-1</b></a><span style="font-weight: 400;"> is an <strong>oncogene-encoded </strong></span><strong>serine/threonine kinase</strong><span style="font-weight: 400;"><strong>.</strong> Originally identified in Maloney murine leukaemia, it is involved in several cellular functions associated with </span><b>survival an proliferation</b><span style="font-weight: 400;"> which confers a</span><b> selective advantage during tumorigenesis</b><span style="font-weight: 400;"> [1,2]. Given this implication, it has been used as a cancer drug target [3].</span></p>
<p><a href="http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=IYZ&amp;sid=2C3I"><span style="font-weight: 400;"><strong>IYZ</strong></span></a> <span style="font-weight: 400;">and</span><strong><a href="http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LY2&amp;sid=1YI3"> LY2</a></strong><span style="font-weight: 400;"> are two</span><b> bioactive inhibitors</b><span style="font-weight: 400;"> of Pim-1. The </span><b>main described interactions</b><span style="font-weight: 400;"> between the protein and these molecules </span><b>are hydrophobic</b><span style="font-weight: 400;">. This can be appreciated in the reference molecule in the picture below (blue residues: </span><span style="font-weight: 400; color: #333399;">Lys67, Asp186, Val52, Ile185, Leu44, Phe49,  Leu174, Ala65</span><span style="font-weight: 400;">), which also shows one hydrogen bond interaction (orange residue: </span><span style="font-weight: 400; color: #ff9900;">Lys67</span><span style="font-weight: 400;">).   </span></p>
<p><strong>Tools using hyd</strong><b>rophobic parameters </b><span style="font-weight: 400;">derived from solvation models, such as a quantum mechanical (QM) version of the MST continuum method used in</span><a href="https://pharmacelera.com/pharmscreen/"><b> Pharm</b><span style="color: #ff6600;"><b>Screen</b></span></a><b>, </b><span style="font-weight: 400;">favours this type of ligand-target interactions.</span></p>
<p><a href="https://pharmacelera.com/wp-content/uploads/2017/12/Crys-blog-1.gif"><img loading="lazy" decoding="async" class="aligncenter wp-image-3258 size-full" src="https://pharmacelera.com/wp-content/uploads/2017/12/Crys-blog-1.gif" alt="" width="640" height="480" /></a></p>
<p><span style="font-weight: 400;">The </span><b>similarity-property principle </b><span style="font-weight: 400;">suggests that analogous compounds will likely share similar biological properties. Indeed, defining the adequate properties that define the biological interactions are fundamental to explore similarity studies. In this case, </span><b>hydrophobicity is an essential interaction </b><span style="font-weight: 400;">to be considered when a ligand-based drug design process is performed.</span></p>
<h3>Alignment</h3>
<p><span style="font-weight: 400;">In order to verify it, <strong>we have aligned IYZ against LY2</strong> using both traditional interaction fields and <a href="https://pharmacelera.com/pharmscreen/"><b>Pharm</b><span style="color: #ff6600;"><b>Screen</b></span></a></span><span style="font-weight: 400;">´s hydrophobic interaction fields and the results have been <strong>compared with the crystal structure</strong>.</span></p>
<p><span style="font-weight: 400;">The picture below shows the<strong> alignment of both approaches</strong> with respect to the <strong>reference molecule in purple</strong>.</span><a href="https://pharmacelera.com/wp-content/uploads/2017/12/merge-1.gif"><img loading="lazy" decoding="async" class="wp-image-3259 size-full aligncenter" src="https://pharmacelera.com/wp-content/uploads/2017/12/merge-1.gif" alt="" width="640" height="480" /></a><span style="font-weight: 400;">When comparing this with the crystallized molecule, the alignment performed considering <strong>traditional interaction fields misses the correct pose</strong> of the molecule, while <a href="https://pharmacelera.com/pharmscreen/"><b>Pharm</b><span style="color: #ff6600;"><b>Screen</b></span></a> </span><span style="font-weight: 400;">is </span><span style="font-weight: 400;">able to<strong> find the bioactive overlay using </strong></span><span style="font-weight: 400;"><strong>hydrophobic interaction</strong> fields, as shown in the picture below</span><span style="font-weight: 400;">. </span></p>
<p><a href="https://pharmacelera.com/wp-content/uploads/2017/12/conclusion-blog.gif"><img loading="lazy" decoding="async" class="wp-image-3257 size-full aligncenter" src="https://pharmacelera.com/wp-content/uploads/2017/12/conclusion-blog.gif" alt="" width="640" height="480" /></a></p>
<p><span style="font-weight: 400;"> Hence, when <strong>searching for new potential hits</strong> in <strong>ligand-based in-silico approaches</strong>, it is crucial to<strong> use models for molecular alignment and similarity that use hydrophobic properties</strong> in situations in which hydrophobicity dominates the interaction between a ligand and a protein, as the one shown in this example.</span></p>
<p><video controls="controls" width="810" height="766"><source src="https://pharmacelera.com/wp-content/uploads/2017/12/Secuencia-02_4.mp4" type="video/mp4" /></video></p>
<p>&nbsp;</p>
<p><script type="text/javascript" src="https://forms.zohopublic.com/albertosalas/form/Learnmore/jsperma/1_fb5e171EF33j3B56C3KmCg2?height=400px&#038;width=766px"" id="ZFScript"></script></p>
<p><small> [1] C. J. Saris, J. Domen, and A. Berns, “The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG.,” EMBO J., vol. 10, no. 3, pp. 655–64, Mar. 1991.</small></p>
<p>[2] J. J. Gu, Z. Wang, R. Reeves, and N. S. Magnuson, “PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis.,” Oncogene, vol. 28, no. 48, pp. 4261–71, Dec. 2009.</p>
<p>[3] Y. Tursynbay, J. Zhang, Z. Li, T. Tokay, Z. Zhumadilov, D. Wu, and Y. Xie, “Pim-1 kinase as cancer drug target: An update.,” Biomed. reports, vol. 4, no. 2, pp. 140–146, Feb. 2016.</p>
<p>The post <a href="https://pharmacelera.com/blog/science/alignment-of-pim-1-inhibitors-with-pharmascreen/">Alignment of PIM-1 Inhibitors with PharmScreen</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		<enclosure url="https://pharmacelera.com/wp-content/uploads/2017/12/Secuencia-02_4.mp4" length="10925761" type="video/mp4" />

			</item>
		<item>
		<title>Ligand-based or structure-based virtual screening?</title>
		<link>https://pharmacelera.com/blog/science/ligand-based-or-structure-based-virtual-screening/</link>
		
		<dc:creator><![CDATA[Enric Gibert]]></dc:creator>
		<pubDate>Fri, 10 Nov 2017 11:30:35 +0000</pubDate>
				<category><![CDATA[Science]]></category>
		<category><![CDATA[Computationall chemistry]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[ligand based]]></category>
		<category><![CDATA[structure based]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://www.pharmacelera.com/?p=3161</guid>

					<description><![CDATA[<p>Virtual screening is a well-known approach in drug discovery projects to find new leads in virtual libraries of small molecules, but it [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/science/ligand-based-or-structure-based-virtual-screening/">Ligand-based or structure-based virtual screening?</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Virtual screening is a well-known approach in drug discovery projects to find new leads in virtual libraries of small molecules, but it is not clear which of the existing techniques is better. </p>
<p>Ligand-based tools are characterized by their speed but do not take into account the receptor while structure-based tools model ligand-receptor interactions but are more compute intensive. </p>
<p>It has been shown that in many projects simpler approaches work better, which might seem counterintuitive, but this is due to the noise introduced by complex models. </p>
<p>What do you think?</p>
<p>The post <a href="https://pharmacelera.com/blog/science/ligand-based-or-structure-based-virtual-screening/">Ligand-based or structure-based virtual screening?</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>New user interface for PharmScreen</title>
		<link>https://pharmacelera.com/blog/upgrades/new-user-interface-for-pharmscreen/</link>
		
		<dc:creator><![CDATA[Enric Gibert]]></dc:creator>
		<pubDate>Wed, 09 Aug 2017 14:45:47 +0000</pubDate>
				<category><![CDATA[Upgrades]]></category>
		<category><![CDATA[computational chemistry]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[PharmaScreen]]></category>
		<category><![CDATA[Virtual screening]]></category>
		<guid isPermaLink="false">https://www.pharmacelera.com/?p=3172</guid>

					<description><![CDATA[<p>Check out our new user interface for PharmScreen! Perform virtual screening campaigns with just a few clicks and take advantage of Pharmacelera&#8217;s [&#8230;]</p>
<p>The post <a href="https://pharmacelera.com/blog/upgrades/new-user-interface-for-pharmscreen/">New user interface for PharmScreen</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Check out our new user interface for <a href="https://pharmacelera.com/pharmscreen/">PharmScreen</a>!</p>
<p>Perform virtual screening campaigns with just a few clicks and take advantage of Pharmacelera&#8217;s unique 3D hydrophobic fields!</p>
<p><a href="https://pharmacelera.com/pharmscreen/">PharmScreen</a> will find you leads with higher chemical diversity, increasing your chances of finding original scaffolds.</p>
<p>The post <a href="https://pharmacelera.com/blog/upgrades/new-user-interface-for-pharmscreen/">New user interface for PharmScreen</a> appeared first on <a href="https://pharmacelera.com">Pharmacelera | Pushing the limits of computational chemistry</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
